Virax Biolabs Group Past Earnings Performance
Past criteria checks 0/6
Virax Biolabs Group's earnings have been declining at an average annual rate of -51%, while the Healthcare industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 48.1% per year.
Key information
-51.0%
Earnings growth rate
2.0%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | 48.1% |
| Return on equity | -78.2% |
| Net Margin | -7,753.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Virax Biolabs Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -7 | 5 | 2 |
| 30 Jun 24 | 0 | -7 | 5 | 2 |
| 31 Mar 24 | 0 | -7 | 5 | 2 |
| 31 Dec 23 | 0 | -7 | 4 | 2 |
| 30 Sep 23 | 0 | -7 | 4 | 3 |
| 30 Jun 23 | 0 | -6 | 4 | 2 |
| 31 Mar 23 | 0 | -5 | 4 | 2 |
| 31 Dec 22 | 0 | -4 | 3 | 1 |
| 30 Sep 22 | 0 | -3 | 2 | 0 |
| 30 Jun 22 | 0 | -2 | 2 | 0 |
| 31 Mar 22 | 0 | -2 | 1 | 0 |
| 31 Dec 21 | 0 | -1 | 1 | 0 |
| 30 Sep 21 | 0 | -1 | 1 | 0 |
| 30 Jun 21 | 0 | -1 | 1 | 0 |
| 31 Mar 21 | 0 | -1 | 1 | 0 |
| 31 Mar 20 | 0 | -1 | 1 | 0 |
Quality Earnings: VRAX is currently unprofitable.
Growing Profit Margin: VRAX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VRAX is unprofitable, and losses have increased over the past 5 years at a rate of 51% per year.
Accelerating Growth: Unable to compare VRAX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VRAX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (10.3%).
Return on Equity
High ROE: VRAX has a negative Return on Equity (-78.19%), as it is currently unprofitable.